Aurobindo Pharma Share Price Gains Over 1% as Stock Nears Multi-Month Breakout


By Dalal Street Investment Journal (DSIJ)

Summary:


Aurobindo Pharma's share price is in focus as the stock nears a multi-month breakout zone. On March 10, the Nifty Pharma index emerged as one of the top gainers, adding further strength to the sectoral mood. Backed by strong technical indicators, improving relative strength and relatively low valuation versus peers, Aurobindo Pharma is drawing market attention.

Breakout Stock to Watch: Aurobindo Pharma, Trades at Low PE

Indian equity benchmark indices traded in the green on Tuesday, March 10, 2026, with the Nifty 50 moving above the 24,100 mark. The main trigger for the rally was easing tension around the Middle East after President Donald Trump said the Iran war could end “very soon” and outlined measures to keep oil prices under control.

Crude Oil Price Ease

WTI crude futures, which had surged to nearly $120 per barrel in the previous session, slipped below $90 on Tuesday. This came after Trump signalled that the conflict may be nearing an end and spoke about steps such as easing sanctions and deploying the US Navy to escort tankers through the Strait of Hormuz. G7 nations also indicated that they were prepared to release oil from strategic reserves if needed.

Nifty Pharma Top Gainer

Most sectoral indices were seen trading higher, with Nifty Pharma emerging as one of the top gainers. The index was up 1.2%, with most of its constituents in the green. Among them, Aurobindo Pharma Ltd drew particular attention.

Aurobindo Pharma Ltd

Trade

128133.69 (2.70 %)

Updated - 10 March 2026
1283.50day high
DAY HIGH
1249.00day low
DAY LOW
1028547
VOLUME (BSE)

Aurobindo Pharma Share Price In Focus; Multi-Month Breakout Likely 

Aurobindo Pharma's share price was trading over 1% higher on Tuesday, March 10, 2026. On the technical charts, the stock appears to be on the verge of a multi-month breakout.

The stock has largely moved within a broad range since January last year. The upper resistance is placed in the ₹1,270 to ₹1,278 zone, while support has remained near ₹1,010. This range has held for more than 14 months, and the stock is now approaching the upper end of this band, making the current zone important from a chart perspective.

Aurobindo Pharma is currently trading above all its key moving averages, namely the 20-day, 50-day, 100-day and 200-day moving averages. More importantly, these averages are aligned in the desired sequence, which points to a favourable trend structure.

The moving average ribbon remains in an uptrend. On the weekly chart, Bollinger Bands are also trending higher, while on the daily chart, they are expanding, indicating a buildup in momentum. The relative strength line is rising and is close to an 11-month high, which shows improving outperformance.

The 14 period daily RSI is also in an uptrend and has rebounded after taking support near its 9 period average, reinforcing the positive bias. At the same time, the daily MACD remains in a strong uptrend and continues to diverge from its 9-period average, which further supports the constructive setup.

Recent Development In The US Market

In a recent business update, the company said that its subsidiary, Eugia Pharma Specialities Limited, has launched Pomalidomide Capsules in 1 mg, 2 mg, 3 mg and 4 mg strengths in the US market.

According to IQVIA MAT data for the 12 months ending January 2026, the US market size for Pomalidomide capsules is estimated at around $3.3 billion. Pomalidomide is a third-generation immunomodulatory drug used along with dexamethasone and, in some cases, bortezomib, for the treatment of relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.

Aurobindo Pharma Valuation Compared With Sun Pharma, Divi’s Lab, Cipla 

From a valuation standpoint, Aurobindo Pharma appears to be trading near its three-year median price-to-earnings multiple of 20.7x, with the stock currently valued at around 20.78x earnings. This suggests that the stock is broadly in line with its own medium term historical valuation band rather than trading at a stretched premium.

When compared with large listed peers in the pharmaceutical space, Aurobindo Pharma stands at the lower end of the valuation spectrum. Sun Pharma trades at 35.85x, Divi’s Laboratories at 67.46x, Torrent Pharma at 64.95x and Cipla at 22.45x. Against this backdrop, Aurobindo Pharma’s valuation looks relatively lower than most major peers, while also remaining close to its own historical median.

Stock Name

PE

Sun Pharma

35.85

Divi’s Laboratories

67.46

Torrent Pharma

64.95

Cipla

22.45

Aurobindo Pharma

20.78

Source: Screener 

Conclusion

With the broader market sentiment improving, pharma stocks finding support, and Aurobindo Pharma nearing the upper end of a long-held trading range, the stock is drawing attention on both technical and business developments. The recent US launch by its subsidiary adds a fresh fundamental trigger, while its valuation remains relatively moderate compared with several large peers. Taken together, these factors make the stock one to watch as it approaches an important technical zone.

Also Read: GIFT Nifty Jumps 400 Points, Crude Oil Slips to $86

About the Author

SEBI Registered Research Analyst (INH000006396).


Founded in 1986, Dalal Street Investment Journal (DSIJ) brings decades of experience in India’s equity markets. DSIJ's research combines fundamental analysis with price action, guided by disciplined risk management and capital preservation. They follow a structured, data-driven approach designed to help investors and traders make informed decisions beyond short-term market noise. 

Published Date : 10 Mar 2026

Disclaimer :

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.


Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 lakh+ Users

icon-with-text

4.7 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,300+ Cr MTF Book

icon-with-text